Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 December 2024
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 19 September 2024Expected publication date: 11 December 2024
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 April 2025
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 April 2025
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 April 2025
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 2 July 2025
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 July 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer after platinum-based chemoradiation ID6223Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treatments for non-small-cell lung cancer [ID6234]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC